Diabetes
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies...
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
News
U.S. kidney transplants grow in number and success
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
News
SGLT2 inhibitor use rising in patients with DKD
News
Empagliflozin gets HFrEF approval from FDA
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...
News
Patients with diabetes more likely to be hospitalized, especially with foot infection
News
ESC heart failure guideline to integrate bounty of new meds
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds...
News
Unmanaged diabetes, high blood glucose tied to COVID-19 severity
Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes...
News
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses